Search results for factors

Factors for consideration

https://www.pharmac.govt.nz/about/annual-review/2014/factors-for-consideration/

Factors for consideration The Factors for Consideration – biggest change to PHARMAC’s decision-making in 21 years PHARMAC is embarking on one of the biggest changes in its 21-year history – changes to the way it makes decisions. This includes decisions about which medicines and medical devices...

Factors for Consideration

https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/

Factors Need To work out what the level of 'need' is we consider the impact of the disease, condition or illness on the person, their family or whānau, wider society, and the broader New Zealand health system. Health benefit Health benefit is about the potential health gain from the medicine...

cultural-factors-in-medicine-taking.pdf

https://www.pharmac.govt.nz/assets/cultural-factors-in-medicine-taking.pdf

Description Cultural Factors in Medicine Taking Referenced from Extracted from PDF of scanned articles supplied by Pharmac (29284321.pdf ) Pat Ngata and Eru Pomare. New Ethicals June, 1992. Cultural Factors in Medicine Taking A Māori Perspective The 1988 Hauora report on Māori Standards of Health...

Factors for consideration

https://www.pharmac.govt.nz/about/2016/factors/

Factors for consideration After meetings across the country to discuss what’s relevant when assessing pharmaceuticals, in 2016 we changed the way we make decisions; the most significant change to PHARMAC’s decision-making in 23 years. Building off what we previously used – decision criteria – our...

Factors for Consideration are coming

https://www.pharmac.govt.nz/about/2015/factors-for-consideration/

Factors for Consideration are coming Foundation work continued towards adopting a new way of making funding decisions – the Factors for Consideration. In late 2014 we announced the current nine Decision Criteria, which have served us well for 22 years, will be replaced by Factors for Consideration...

Questions and answers about the Factors for Consideration

https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/questions-and-answers/

Questions and answers about the Factors for Consideration What are the Factors for Consideration all about? PHARMAC is responsible for making decisions on the funding of medicines, vaccines and medical devices. The Factors for Consideration guide this decision-making, and help PHARMAC to achieve...

How the Factors for Consideration affect Named Patient Pharmaceutical Assessment (NPPA)

https://www.pharmac.govt.nz/tools-resources/forms/exceptional-circumstances/nppa-with-factors/

How the Factors for Consideration affect Named Patient Pharmaceutical Assessment (NPPA) Who can make a NPPA application? Only authorised prescribers may submit NPPA applications, within their scope of practice. Only District Health Board (DHB) clinicians may submit Rapid Assessment NPPA...

Decision Criteria review

https://www.pharmac.govt.nz/about/operating-policies-and-procedures/decision-criteria-consultation

Decision Criteria, including proposed changes. We consulted widely across New Zealand as part of this review. The outcome of this review was a change to the way PHARMAC makes funding decisions, with new Factors for Consideration replacing the Decision Criteria. Introducing the Factors for Consideration...

Making funding decisions

https://www.pharmac.govt.nz/about/your-guide-to-pharmac/factsheet-04-making-funding-decisions/

the most improvement to the health of New Zealanders. All New Zealanders are, in some way and at some time, affected by the funding decisions we make. To ensure our decisions are as fair and robust as possible we currently use the Factors for Consideration, along with expert clinical advice. We...

How medicines are funded

https://www.pharmac.govt.nz/medicines/how-medicines-are-funded

(PHARMAC and clinical advisors) using factors for consideration Review application, collate additional information and undertake preliminary analysis Either or both: PTAC advice Subcommittee or other clinical advice Recommendations: Positive Decline Assess relative value (PHARMAC) using factors...

PHARMAC's engagement - an external view

https://www.pharmac.govt.nz/about/2015/chairs-review/pharmacs-engagement-an-external-view/

PHARMAC's engagement - an external view Development of the Factors for Consideration reflects a sea change in how PHARMAC engages with its stakeholders, says Kate Russell For consultation to be meaningful, it has to be authentic. That’s something PHARMAC does well and one of the positive changes...

Supporting information

https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/supporting-information/

Supporting information This supporting information provides additional explanation of the Factors for Consideration. This is a living document that will be regularly updated to reflect any changes or to link to new information that may provide additional clarification. This document intends...

Operating policies and procedures

https://www.pharmac.govt.nz/about/operating-policies-and-procedures

      Amending the Schedule 2.3      Procedure for considering an application for funding 2.4      Special Authorities 2.5      Hospital Medicines restriction 2.6      Exceptions 3.    How we secure the best health outcomes from available funding 3.1      Factors for Consideration 3.2      PHARMAC’s strategies...

Inpharmation in hospitals - May 2015

https://www.pharmac.govt.nz/newsletters/inpharmation-in-hospitals/inpharmation-in-hospitals-2015-05/

Inpharmation in hospitals - May 2015 Your update on PHARMAC's latest work in hospital medicines Issue 1, May 2015 In this issue: Updating you on PHARMAC’s activity in hospitals Abiraterone funded from 1 May Biologics and biosimilars Factors for Consideration: changing the way we make funding...

consultation-2013-09-26-haemophilia-treatments.pdf

https://www.pharmac.govt.nz/assets/consultation-2013-09-26-haemophilia-treatments.pdf

of the following haemophilia treatments in Section B (Community Pharmaceuticals) of the Pharmaceutical Schedule: o o Recombinant blood factors (VIIa, VIII and IX); and Factor eight inhibitor bypassing agent (FEIBA). Funded access to these treatments would continue to be via the National Haemophilia...

Inpharmation - March 2015

https://www.pharmac.govt.nz/newsletters/inpharmation/inpharmation-2015-03/

Inpharmation - March 2015 In this issue: From the Chief Executive Seminar Series – check out our video channel Stakeholder survey Factors for Consideration arriving this year Blood glucose meters for diabetes – seeking your views Rare disorders medicines process Rātana Pā hauora tent – non-Māori...

1 Background | PHARMAC

https://www.pharmac.govt.nz/assets/_generated_pdfs/1-background-2047.pdf

. Assessment of a proposal against the Factors for Consideration is supported by the use of economic analyses as described in this document. PHARMAC’s preferred method is ‘cost-utility analysis’ as defined in this document; although cost-minimisation analyses may be sufficient for some proposals...

Managing the risks of polypharmacy in chronic disease

https://www.pharmac.govt.nz/seminars/seminar-resources/polypharmacy/

of polypharmacy - Fiona Corbin Human factors influencing safe medicines use – patient and prescriber - Dr Brian Robinson Pharmacodynamic principles for safe practice (getting the dose right, common drug and disease interactions) - Dr Tim Maling Prescribing appropriately (worked examples) - Dr Tim...

decision-criteria-summary-of-submissions-2014-07.pdf

https://www.pharmac.govt.nz/assets/decision-criteria-summary-of-submissions-2014-07.pdf

PHARMAC makes its funding decisions. The proposed decision-making matrix itself was supported by most respondents, though a number of submitters questioned how weightings would apply, and there was some confusion as to whether size of boxes corresponded with the importance of a given factor. Many...

rfp-2015-02-02-haemophilia-products.pdf

https://www.pharmac.govt.nz/assets/rfp-2015-02-02-haemophilia-products.pdf

2 February 2015 Dear Supplier REQUEST FOR PROPOSALS – SUPPLY OF RECOMBINANT FACTOR VIII, RECOMBINANT FACTOR IX, RECOMBINANT FACTOR VIIa AND FACTOR VIII INHIBITOR BYPASSING FRACTION FOR HAEMOPHILIA PHARMAC invites proposals for the supply of Recombinant Factor VIII, Recombinant Factor IX...

Schedule Online

https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php?code=A040401

% 2 ml Tranexamic acid Tab 500 mg Octocog alfa [Recombinant factor VIII] (Advate) Inj 250 iu vial; Inj 500 iu vial; Inj 1,000 iu vial; Inj 1,500 iu vial; Inj 2,000 iu vial; Inj 3,000 iu vial Eptacog alfa [Recombinant factor VIIa] Inj 1 mg syringe; Inj 2 mg syringe; Inj 5 mg syringe; Inj 8 mg syringe...

OPERATING POLICIES

https://www.pharmac.govt.nz/assets/opp-2016-08-3rd-ed-rev.pdf

. When PHARMAC makes amendments to the listing of pharmaceuticals in the Schedule, it uses the Factors for Consideration as set out in clause 2.2 of these operating policies and procedures. 1.2.3 As an agency of the Government, PHARMAC has obligations under public law. Public law controls...

Health Inequalities Research Programme

https://www.pharmac.govt.nz/assets/final-ethnic-ineq.pdf

in Aotearoa: • Trends in life expectancy since European contact • Cause specific mortality trends in last 25 years 3. Explanations for ethnic inequalities: • socioeconomic position • health services • risk factors (e.g. tobacco) • racism 4. What might Pharmac do? 2 Index Indigenous health inequalities • All...

Supply side RFP template

https://www.pharmac.govt.nz/assets/rfp-2018-07-23-haemophilia.pdf

23 July 2018 Dear Supplier REQUEST FOR PROPOSALS – SUPPLY OF RECOMBINANT FACTOR VIII, RECOMBINANT FACTOR IX AND BYPASSING AGENTS FOR THE TREATMENT OF HAEMOPHILIA PHARMAC invites proposals for the supply of Recombinant Factor VIII, Recombinant Factor IX and bypassing agents (Recombinant Factor VIIa...

1 Background

https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/pfpa/1-background/

staff, pharmaceutical companies, and other health economists. It provides guidance on methods for any economic assessment that will help to inform a PHARMAC funding decision. Assessment of a proposal against the Factors for Consideration is supported by the use of economic analyses as described...

Schedule Online

https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php?code=A0404

factor VIIa]; Factor eight inhibitor bypassing fraction; Moroctocog alfa [Recombinant factor VIII]; Nonacog alfa [Recombinant factor IX]; Nonacog gamma, [Recombinant Factor IX]; Octocog alfa [Recombinant factor VIII] (Advate); Octocog alfa [Recombinant factor VIII] (Kogenate FS); Sodium tetradecyl sulphate; Tranexamic acid Vitamin K Phytomenadione...

Summary of submissions

https://www.pharmac.govt.nz/about/operating-policies-and-procedures/decision-criteria-consultation/summary-of-submission...

factors may be given more weighting, others questioned if weightings of factors for given decisions could be made more transparent. Overall it was unclear amongst these submitters if, how and when weightings were applied in PHARMAC’s decision making. PHARMAC does not prescribe numerical weightings...

Inpharmation - August 2015

https://www.pharmac.govt.nz/newsletters/inpharmation/inpharmation-2015-08/

Inpharmation - August 2015 In this issue: From the Chief Executive Public help us refresh our decision making: Factors for Consideration Talking with suppliers and diabetes groups about blood glucose meters and test strips Haemophilia treatment changes Late stage prostate cancer drug - abiraterone...

consultation-2014-02-19-dcc.pdf

https://www.pharmac.govt.nz/assets/consultation-2014-02-19-dcc.pdf

....................................................................................................... 6 2.1 Application of the factors PHARMAC considers when making funding decisions .... 7 2.2 Provide a decision-making matrix ........................................................................... 8 2.3 Place the decision-making matrix within the broader framework that PHARMAC operates within...

1

https://www.pharmac.govt.nz/assets/ptac-haematology-subcommittee-minutes-2016-4.pdf

be accompanied by a robust audit process to monitor use and outcomes. 2 New haemophilia treatments – update 2.1 The Subcommittee noted a paper by PHARMAC staff requesting updated clinical advice on potential future haemophilia treatments, specifically on long-acting recombinant factor VIII (rFVIII...